The Global Tribune

Cold Agglutinin Disease (CAD) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

 Breaking News
  • No posts were found

Cold Agglutinin Disease (CAD) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

March 16
16:25 2020
Cold Agglutinin Disease (CAD) Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight

cold agglutinin disease market

 

DelveInsight’s “Cold Agglutinin Disease (CAD) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Cold Agglutinin Disease (CAD), historical and forecasted epidemiology as well as the Cold Agglutinin Disease (CAD) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

DelveInsight has launched a new report on Cold Agglutinin Disease Market Insights, Epidemiology and Market Forecast-2030

Cold agglutinin disease (CAD) is an uncommon autoimmune hemolytic anemia in which awell-defined, clonal low-grade lymph proliferative disorder of the bone marrow results inerythrocyte destruction mediated by the classical complement pathway. It is mediated bycold agglutinins (CA), without any underlying disease such as aggressive lymphoma, otherovert malignancies, or specific infections.

CAD are able to agglutinate red blood cells (RBC) atan optimum temperature of 3–4°C, but are also active at higher temperatures, dependingon the thermal amplitude. Symptoms get worse in cold weather.Cold agglutinin disease is a type of autoimmune hemolytic anemia’s (AIHAs). AIHA consist ofwarm, cold, or mixed-reactive antibody types that are directed against antigens on the redblood cell (RBC) surface.

 

Request for Sample Pages: https://www.delveinsight.com/sample-request/cold-agglutinin-disease-cad-market

 

Cold Agglutinin Disease (CAD) Epidemiology 

The Cold Agglutinin Disease (CAD) epidemiology division provide insights about historical and current Cold Agglutinin Disease (CAD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Some of the Report Key facts:-

  1. The prevalence of AIHA is estimated to be 17 per 100,000 cases, which has been based on the Denmark study.
  2. A large series of CAD cases where the study identified that 68% of cases belongs to primary CAD and 32% belong to secondary CAD.
  3. A prevalence of 16.2 cases per million and an incidence rate of 1.0 CAD cases per million people per years in the Norwegian population.

 

Report Key Benefits

    1. Cold Agglutinin Disease market report covers a descriptive overview and comprehensive insight of the Cold Agglutinin Disease epidemiology Cold Agglutinin Disease market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

    2. Cold Agglutinin Disease market report provides insights on the current and emerging therapies. 

    3. Cold Agglutinin Disease market report offers a global historical and forecasted market covering drug outreach in 7 MM.

    4. Cold Agglutinin Disease market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease market.

 

  “According to DelveInsight’s analysis, CAD frequency is usually more in females than in males. The male to female ratio is around 45:55

 

 Some of the key companies working on CAD that are given below-

  1. Sanofi- Multinational Pharmaceutical Company
  2. ApellisPharmaceuticals
  3. Janssen Pharmaceuticals

 

  Name of covered Drugs are given below.

  1. Sutimlimab
  2. APL-2
  3. Bortezomib

 

Table of Contents

1. Key Insights

2. Executive Summary of Cold Agglutinin Disease (CAD)

3. Competitive Intelligence Analysis for Cold Agglutinin Disease (CAD)

4. Cold Agglutinin Disease (CAD): Market Overview at a Glance

4.1. Cold Agglutinin Disease (CAD) Total Market Share (%) Distribution in 2017

4.2. Cold Agglutinin Disease (CAD) Total Market Share (%) Distribution in 2030

5. Cold Agglutinin Disease (CAD): Disease Background and Overview

6. Patient Journey

7. Cold Agglutinin Disease (CAD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Cold Agglutinin Disease (CAD) Treatment and Management

8.2. Cold Agglutinin Disease (CAD) Treatment Algorithm 

9. Unmet Needs

10. Key Endpoints of Cold Agglutinin Disease (CAD) Treatment

11. Marketed Products

12. Emerging Therapies

13. Cold Agglutinin Disease (CAD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Cold Agglutinin Disease (CAD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Why should you buy this CAD market report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Cold Agglutinin Disease (CAD) market
  • To understand the future market competition in the Cold Agglutinin Disease (CAD) market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease (CAD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Cold Agglutinin Disease (CAD) market
  • To understand the future market competition in the Cold Agglutinin Disease (CAD) market

 

Related Reports:-

1.     Cold Agglutinin Disease (CAD) – Pipeline Insights, 2020

The Cold Agglutinin Disease (CAD) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cold Agglutinin Disease (CAD) across the complete product development cycle, including all clinical and nonclinical stages.

2.     Cold Agglutinin Disease (CAD) – Epidemiology Forecast to 2030

The Cold Agglutinin Disease (CAD) report covers a detailed overview explaining its causes, symptoms, and classification, pathophysiology, diagnosis and treatment patterns

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/